Literature DB >> 27895756

Role of microRNA-4458 in patients with non-small-cell lung cancer.

Lidao Bao1, Linlin Wang2, Guomin Wei2, Yuehong Wang3, Gerile Wuyun3, Agula Bo3.   

Abstract

Incidence and progression of non-small-cell lung cancer (NSCLC) is a multi-factor, multi-step process. The present study investigated the association between the expression level of microRNA (miR)-4458 in NSCLC and paracarcinoma liver tissues and survival rates, and studied the biological functions of miR-4458 at the cellular and protein level. NSCLC and paracarcinoma tissues were sequenced using a miR expression chip. The association between miR-4458 expression and tumor-node-metastasis staging, total survival rate and relapse-free survival rate was analyzed. miR-4458 was subjected to target gene prediction. The target protein of cyclin D1 (CCND1) was verified with western blot analysis, immunohistochemistry and a luciferase reporter assay. The relative level of miR-4458 in paracarcinoma tissues of 9 NSCLC patients decreased from 2.38 to 0.65 (P<0.001). Total five-year survival rates of the high-expression miR-4458 group (29.21%) significantly exceeded that of the low-expression group (14.37%) (P=0.025). The viability of human lung carcinoma A549 and H460 cells transfected with miR-4458 decreased significantly compared with cells transfected with a normal control (blank control plasmid) within 72 h (P<0.001). The percentage of A549 and H460 cells transfected with a miR-4458 mimic at the cell cycle stage G0/G1 was 69.94±8.05 and 68.15±7.75%, respectively. The percentages increased significantly compared with the control group (46.06±6.93 for A549 cells; 45.22±7.24 for H640 cells; P<0.001). CCND1 mRNA was downregulated significantly in H460 cells 72 h subsequent to the addition of miR-4458 mimics (P<0.001). The activity of mutant-CCND1 altered slightly, while the fluorescence intensity of the wild-type-CCND1 group decreased significantly following the addition of miR-4458 mimics. In conclusion, miR-4458 was expressed at low levels in lung cancer tissues, and it arrested cells in vitro at stage G0/G1 and inhibited cell proliferation. Therefore, miR-4458 may participate in the onset of lung cancer as a suppressor gene by inhibiting CCND1.

Entities:  

Keywords:  cancer suppressor gene; cyclin D1; miR-4458; non-small-cell lung cancer

Year:  2016        PMID: 27895756      PMCID: PMC5104218          DOI: 10.3892/ol.2016.5176

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  49 in total

1.  Mutual antagonism of the paired-type homeobox genes, vsx2 and dmbx1, regulates retinal progenitor cell cycle exit upstream of ccnd1 expression.

Authors:  Loksum Wong; Namita Power; Amanda Miles; Vincent Tropepe
Journal:  Dev Biol       Date:  2015-04-11       Impact factor: 3.582

2.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.

Authors:  Zhijiu Zhong; Wen-Shuz Yeow; Chunhua Zou; Richard Wassell; Chenguang Wang; Richard G Pestell; Judy N Quong; Andrew A Quong
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Research ethics committee auditing: the experience of a university hospital.

Authors:  Daniela Marchetti; Angelico Spagnolo; Marina Cicerone; Fidelia Cascini; Giuseppe La Monaca; Antonio G Spagnolo
Journal:  HEC Forum       Date:  2013-09

4.  Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer.

Authors:  Kai-Ze Zhong; Wei-Wen Chen; Xiao-Yan Hu; An-Li Jiang; Jian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Correlation between miR-23a and onset of hepatocellular carcinoma.

Authors:  Lidao Bao; Jianfen Zhao; Xiaoxia Dai; Yi Wang; Ruilian Ma; Yila Su; Hongwei Cui; Jianxiang Niu; Shiming Bai; Zhiying Xiao; Hongwei Yuan; Zhou Yang; Changqing Li; Rui Cheng; Xianhua Ren
Journal:  Clin Res Hepatol Gastroenterol       Date:  2014-01-10       Impact factor: 2.947

6.  Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.

Authors:  Byung Woo Jhun; Kyung-Jong Lee; Kyeongman Jeon; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Joon Young Choi; Kyung Soo Lee; Joungho Han; Sang-Won Um
Journal:  Lung Cancer       Date:  2013-03-22       Impact factor: 5.705

7.  Identification of featured biomarkers in different types of lung cancer with DNA microarray.

Authors:  Chao Zhou; Hao Chen; Li Han; An Wang; Liang-An Chen
Journal:  Mol Biol Rep       Date:  2014-07-08       Impact factor: 2.316

8.  Risk miRNA screening of ovarian cancer based on miRNA functional synergistic network.

Authors:  Huanchun Ying; Jing Lyu; Tianshu Ying; Jun Li; Shanshan Jin; Jingru Shao; Lili Wang; Hongying Xu
Journal:  J Ovarian Res       Date:  2014-01-21       Impact factor: 4.234

9.  Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer.

Authors:  Ming-Zhe Ma; Chun-Xiao Li; Yan Zhang; Ming-Zhe Weng; Ming-di Zhang; Yi-Yu Qin; Wei Gong; Zhi-Wei Quan
Journal:  Mol Cancer       Date:  2014-06-23       Impact factor: 27.401

10.  Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer.

Authors:  Dong Soo Lee; Yeon Sil Kim; Chul Seung Kay; Sung Hwan Kim; Chang Dong Yeo; Jin Woo Kim; Seung Joon Kim; Young Kyoon Kim; Yoon Ho Ko; Jin Hyoung Kang; Kyo Young Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

View more
  2 in total

1.  MicroRNA-4458 suppresses the proliferation of human lung cancer cells in vitro by directly targeting Lin28B.

Authors:  Chang-Hong Liu; De-Sheng Lv; Mo Li; Ge Sun; Xue-Fei Zhang; Yu Bai
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

2.  MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells.

Authors:  Yu Ma; Xuena Li; Song Chen; Bulin Du; Yaming Li
Journal:  Cancer Manag Res       Date:  2019-01-10       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.